Quon Tezz, Lin Li-Chiung, Ganguly Amlan, Hudson Brian D, Tobin Andrew B, Milligan Graeme
Centre for Translational Pharmacology, School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
Centre for Translational Pharmacology, School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
J Biol Chem. 2025 Jan;301(1):108035. doi: 10.1016/j.jbc.2024.108035. Epub 2024 Nov 29.
Agonist-independent, or constitutive, activity is an integral feature of G protein-coupled receptors, but its relevance in pathophysiological settings is generally poorly explored. GPR35 is a therapeutic target in inflammatory diseases of the lower gut. In colonic organoids from a human GPR35a-expressing transgenic mouse line, the GPR35 inverse agonist CID-2745687 increased barrier permeability substantially, indicating that constitutive receptor activity contributes to maintaining epithelial barrier integrity. High constitutive activity of GPR35 was also observed in both HT-29 and HEPG2 cells that express GPR35 endogenously. Mechanistic investigations in recombinant in vitro systems revealed that the constitutive activity of GPR35a was biased and not equivalent across signaling pathways. Hence, no constitutive interactions of the receptor with arrestin-adaptor proteins or activation of Gα-containing G protein heterotrimers were detected while, even at low GPR35a expression levels, substantial constitutive activation of heterotrimers containing either Gα or Gα was observed. Similar biased constitutive activity was observed for the human GPR35b isoform. The extent of constitutive and agonist-mediated activity was dependent on receptor expression level. At high receptor levels, constitutive activation of Gα or Gα masked any agonist-induced effects while low expression levels with low constitutive activity allowed measurement of agonist-induced responses. These results highlight roles, selectivity, and the extent of constitutive activity of GPR35 in cells and tissues that express this receptor endogenously and highlight the contribution of its constitutive activity to maintaining the colonic epithelial barrier, potentially limiting the development of inflammatory bowel diseases.
不依赖激动剂的,即组成型活性,是G蛋白偶联受体的一个固有特征,但其在病理生理环境中的相关性通常鲜有深入研究。GPR35是下消化道炎症性疾病的一个治疗靶点。在来自表达人GPR35a的转基因小鼠品系的结肠类器官中,GPR35反向激动剂CID-2745687显著增加了屏障通透性,表明组成型受体活性有助于维持上皮屏障完整性。在天然表达GPR35的HT-29和HEPG2细胞中也观察到GPR35的高组成型活性。重组体外系统中的机制研究表明,GPR35a的组成型活性具有偏向性,在不同信号通路中并不相同。因此,未检测到该受体与抑制蛋白衔接蛋白的组成型相互作用或含Gα的G蛋白异源三聚体的激活,而即使在低GPR35a表达水平下,也观察到了含Gα或Gα的异源三聚体的大量组成型激活。人GPR35b亚型也观察到类似的偏向性组成型活性。组成型和激动剂介导的活性程度取决于受体表达水平。在高受体水平时,Gα或Gα的组成型激活掩盖了任何激动剂诱导的效应,而低表达水平和低组成型活性则允许测量激动剂诱导的反应。这些结果突出了GPR35在天然表达该受体的细胞和组织中的作用、选择性和组成型活性程度,并突出了其组成型活性对维持结肠上皮屏障的贡献,这可能会限制炎症性肠病的发展。